Subcutaneous immunoglobulin replacement following CD19‐specific chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia in pediatric patients

Cost–utility analysis comparing hospital‐based intravenous immunoglobulin with home‐based subcutaneous immunoglobulin in patients with secondary immunodeficiency

(2019) Tanja M. Windegger et al.   VOX SANGUINIS

Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: A prospective economic analysis

(2018) Lisa W. Fu et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies

(2018) Rajiv Mallick et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Update on the use of immunoglobulin in human disease: A review of evidence

(2017) Elena E. Perez et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy

(2012) J. S. Orange et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies

(2011) Melvin Berger et al.   CLINICAL IMMUNOLOGY

Improved Quality of Life, Immunoglobulin G Levels, and Infection Rates in Patients with Primary Immunodeficiency Diseases during Self-Treatment with Subcutaneous Immunoglobulin G

(2011) Melvin Berger et al.   SOUTHERN MEDICAL JOURNAL

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

(2010) Jordan S. Orange et al.   CLINICAL IMMUNOLOGY